Are Early Access Programmes the Better Funding Pathway for Biotechs?
Many biotech executives we currently meet report difficulties in securing their next financing round to
Many biotech executives we currently meet report difficulties in securing their next financing round to
What is DiGA in short? DiGA, short for Digitale Gesundheitsanwendungen, translates to Digital Health Applications
The U.S. pharmaceutical landscape is set for another major shift. On May 12th, President Trump
France’s Reimbursed Early Access Programs (EAP) provide opportunities for reimbursement of new and innovative drugs
January 12th marked the launch of Joint Clinical Assessment (JCA), a key milestone in the
What is NTAP The New Technology Add-On Payment (NTAP) is a reimbursement program under the
Justin Stindt Consultants is a fast growing consulting company offering strategy & market access consulting services to leading pharmaceutical, biotech and medical device clients. We operate in Europe and the United States.
